Shamekh, Shahram

Shamekh, Shahram was paid $1.37M by Medicaid between Jan 2018 and Dec 2024, across 60 billing codes. Its largest line is 99215, doctor's office visit, returning patient (complex) — 23% of everything it billed.

33Billing provider infoSHAMEKH, SHAHRAM
GREAT NECK, NY 11021

33aNPI1063468627assigned 05/25/2006

33bProvider typeInternal Medicine Physician

28Total paid$1.37M

24GClaims45,344

24DCodes billed60

24AFirst – last monthJan 2018 – Dec 2024

Compared with peers

Next to other Internal Medicine Physician providers in New York

Rank by total paid#205 of 6,049

Median peer was paid$11K

This provider vs. median122×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	2,291	$40K
2019	4,114	$84K
2020	7,486	$247K
2021	9,185	$268K
2022	8,366	$276K
2023	8,541	$277K
2024incomplete	5,361	$183K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99215	Doctor's office visit, returning patient (complex)Prolong outpt/office vis	23%	3,526	2,732	$321K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	13%	3,837	2,979	$177K
94060		5.9%	2,323	2,311	$81K
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	4.8%	1,014	885	$66K
93922		4.7%	1,208	1,191	$65K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	4.5%	3,198	3,045	$62K
96116		4.5%	1,573	1,558	$62K
99487	Ccm add 20min	4.2%	807	807	$57K
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	3.5%	1,614	1,422	$48K
87811	Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19)	2.9%	2,571	2,205	$39K
99497		2.1%	859	841	$29K
G0506	Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service)	2.1%	940	936	$28K

48 more codes

94729		2.0%	929	$28K
95923		2.0%	523	$27K
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	1.8%	1,832	$24K
93000		1.8%	2,086	$24K
90677		1.7%	99	$23K
90651		1.3%	79	$18K
90670		1.3%	88	$18K
94726		1.3%	939	$18K
99498		1.1%	645	$15K
94640	Pressurized or nonpressurized inhalation treatment for acute airway obstruction	<1%	1,628	$13K
99396	Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years	<1%	146	$12K
99395	Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years	<1%	144	$12K
94690		<1%	434	$11K
G0446	Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes	<1%	814	$10K
90682		<1%	156	$8K
G0444	Annual depression screening, 5 to 15 minutes	<1%	721	$7K
95943		<1%	242	$6K
31575		<1%	136	$6K
99205	Prolong outpt/office vis	<1%	52	$5K
95004	Percutaneous tests with allergenic extracts, immediate type reaction	<1%	46	$5K
99354		<1%	378	$4K
95924		<1%	106	$4K
94200		<1%	631	$4K
99355		<1%	362	$3K
J3411	Injection, thiamine hcl, 100 mg	<1%	2,641	$3K
90636		<1%	27	$3K
99490	Ccm add 20min	<1%	188	$3K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	<1%	19	$3K
J3420	Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg	<1%	2,882	$2K
90472	Immunization administration, each additional vaccine (list separately)	<1%	172	$2K
31231		<1%	24	$2K
G0442	Annual alcohol misuse screening, 5 to 15 minutes	<1%	494	$2K
G0009	Administration of pneumococcal vaccine	<1%	196	$2K
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	173	$2K
96132		<1%	165	$1K
94762		<1%	405	$1K
G0008	Administration of influenza virus vaccine	<1%	187	$1K
99358	Prolong nursin fac eval 15m	<1%	74	$996.14
G0447	Face-to-face behavioral counseling for obesity, 15 minutes	<1%	141	$956.77
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	172	$725.63
99407		<1%	27	$553.95
99359	Prolong nursin fac eval 15m	<1%	73	$475.78
90674		<1%	13	$321.56
90686		<1%	21	$300.06
99072		<1%	351	$210.00
96156		<1%	17	$176.66
90662		<1%	16	$134.37
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	180	$35.66

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.